The 30-second summary
- "Microdosing" is not a tested regimen. We could find no randomised trial of doses below the licensed ones, for weight or for anything else.
- The closest evidence is about low licensed doses, and it is mixed: a lower dose kept off more weight than stopping, but less than staying on the full dose.
- The known risks come from the method: pens built for fixed doses, compounded vials that nobody reviews before sale, and "research-grade" peptides that are not medicines at all.
What people mean by microdosing
Search the word and you find several different ideas sharing it.
- Staying on a low licensed dose, because it is working or because the next step brings side effects. This is a conversation with your prescriber, and the prescribing information makes room for it.
- Taking less than the lowest licensed dose, or a fraction of a prescribed dose, from a compounded vial or a pen.
- Spacing doses further apart than once a week.
The 2025 joint advisory from four US nutrition and obesity medicine societies lists all three kinds of use, "microdosing", spaced-out dosing and lower compounded dosing, and says people do it for personal preference, to ease stomach side effects, to cut costs and because of shortages. These carry very different levels of risk, so it matters which one someone means.
Why people do it
Cost is a large part of it. The joint advisory notes that rationing medicine because of cost is more common among people who are younger, female, on lower incomes, uninsured, or living with obesity or cardiovascular disease.
A 2026 report for nurse practitioners names two other drivers: stomach side effects, and what it calls "vanity weight". It also points to something less often said. Weight bias from healthcare providers can push people away from their clinic and towards unregulated sources, including medical spas and websites selling "research-grade" peptides.
What the evidence shows
Doses below the licensed ones: no trials. We could find no randomised trial on PubMed. A 2026 narrative review in Cureus, written by authors who see a possible role for microdosing, concluded that the direct evidence is limited, that more direct studies are needed, and that it should only be started after a thorough discussion with a licensed prescriber.
A lower licensed dose to keep weight off: one trial. SURMOUNT-MAINTAIN, published in The Lancet in 2026 and funded by the manufacturer, took adults who had reached 10 or 15 mg of tirzepatide and randomly assigned them for a further year.
| For the final year | Weight change from the very start | Needed rescue treatment for regaining more than half |
|---|---|---|
| Stayed on 10 or 15 mg | 21.9% lower | 8% |
| Dropped to 5 mg | 16.6% lower | 25% |
| Switched to placebo | 9.9% lower | 67% |
5 mg is a licensed maintenance dose, not a microdose. (See staying on a lower GLP-1 dose.)
Staying on a starting dose: one small study. A 2026 study in Japan followed 112 adults without diabetes who started tirzepatide at 2.5 mg. After 4 weeks, each person and their doctor decided whether to stay on 2.5 mg or move up to 5 mg. At 6 months, weight loss was similar: 15.3% on 2.5 mg and 16.1% on 5 mg. Side effects, mostly stomach-related, were reported by 35% on 2.5 mg and 50% on 5 mg.
That result is worth knowing, and worth reading carefully. The study was not randomised, so people who were already doing well on 2.5 mg may have been the ones who stayed there. It lasted 6 months. Everyone had diet and exercise counselling, and 96.4% followed the diet advice. And the average BMI was 30.8, against 40.1 in SURMOUNT-MAINTAIN. It does not show that 2.5 mg works as well for everyone, and it says nothing about doses below 2.5 mg.
What stopping does. Stopping altogether is the other end of the scale, and here the evidence is clear. A year after stopping semaglutide in the STEP 1 trial, people had regained about two-thirds of the weight they had lost. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% of their body weight over a year. (See what happens when you stop a GLP-1 and when food noise comes back.)
Where the real risks are
Pens are built for whole doses. Mounjaro's UK prescribing information says each KwikPen contains 4 doses of 0.6 ml, that any solution left after those should be thrown away, and that its instructions must be followed carefully. It gives no instructions for taking part of a dose.
Compounded products are not the licensed medicine. The FDA says compounded drugs are not FDA-approved and that it does not review them for safety, effectiveness or quality before they are sold. It has warned about products made with salt forms of semaglutide, which are different active ingredients, and has received reports of adverse events, some needing hospital treatment, that may be linked to dosing errors with compounded semaglutide. By 31 May 2026 it had received 990 adverse event reports linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. Many compounded products also carry added ingredients. (See tirzepatide with niacinamide or B12 and compounded semaglutide and tirzepatide.)
"Research-grade" peptides are not medicines. They are sold outside any regulated supply chain, and the 2026 nurse practitioner report lists them among the main safety risks.
In the UK, the MHRA says GLP-1 medicines supplied as a powder in vials are not authorised, that these medicines should not be bought from beauty salons, social media or anywhere without a prior consultation with a healthcare professional, and that you can check a pharmacy is registered with the General Pharmaceutical Council.
Less effect, and unknown nutrition. The joint advisory warns that off-label use can lead to dosing errors and reduced effect, and says that what it means for nutrition is still unclear.
The prescriber-led version of the same goal
Most of what people want from microdosing, fewer side effects, a smaller dose, a plan for keeping weight off, can be pursued inside the licence.
- Side effects during dose increases. Wegovy's UK prescribing information lets a prescriber delay the next increase, or go back to the previous dose, if stomach side effects are significant. The joint advisory notes that in the trials people could stay on a dose for up to 8 weeks to let side effects settle. (See pausing a dose increase.)
- The lowest dose that works. The same advisory says some of its authors keep people at the lowest effective dose and increase it only when weight loss stops or the effect wanes.
- Stepping down later. For tirzepatide, 5 mg is a licensed maintenance dose with trial data behind it.
- Shared decisions. A 2026 European consensus statement recommends shared decision making on whether to start, increase, delay, pause, reduce or stop these medicines, and lists different dosing schedules among the questions that still need research.
Questions to take to your prescriber:
- Is my current dose already doing what I need?
- Could we pause, go back a step or stay longer on this dose, rather than going up?
- If I reach my goal, what would a lower maintenance dose look like, and what would make us go back up?
- How will we tell if it is working, and what should I watch for?
Specific situations have their own pages: microdosing in perimenopause and menopause and microdosing for inflammation, joint pain and a calmer mind.
What to do with this
The calculator works with licensed doses. If you and your prescriber settle on a lower one, enter that dose: the appetite ceiling depends on dose, so a lower dose usually means you can eat more, and a protein floor that is easier to reach.
Sources
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars 2025. PubMed
- Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract 2026. PubMed
- Panlilio MA, et al. Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. Cureus 2026. PubMed
- Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2026. PubMed
- Amioka M, et al. Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults. Diabetes Obes Metab 2026. PubMed
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022. PubMed
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024. PubMed
- Mounjaro KwikPen solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
- Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics. electronic medicines compendium. emc
- US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
- Medicines and Healthcare products Regulatory Agency. GLP-1 medicines for weight loss and diabetes: what you need to know. gov.uk
- Dobbie LJ, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults: an EASO, EFAD, and ECPO Consensus Statement. Lancet Diabetes Endocrinol 2026. PubMed
Medical disclaimer: Articles in the foodose research library are educational, not medical advice. Never change, split or space out your dose without your prescriber. See our full medical disclaimer.